Stage III Melanoma: Clinical Trials

10 trials for Stage III Melanoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 1 terminated, 1 unknown. 10 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 110Completed 8, Terminated 1, Unknown 1
Phase 24Completed 3, Terminated 1

Follow Stage III Melanoma: new trials by email Literature Review of Stage III Melanoma trials Research Report on Stage III Melanoma

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors
TBX-3400 - Stage III Melanoma, Stage IV Melanoma
Phase 1UnknownTaiga Biotechnologies, Inc.722019-06-022022-05-03
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
Pembrolizumab with All-Trans Retinoic Acid - Stage IV Melanoma, Stage III Melanoma
Phase 1 / Phase 2CompletedUniversity of Colorado, Denver262017-10-312024-10-01
Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma
IMP321 (eftilagimod alpha), Pembrolizumab - Stage IV Melanoma, Stage III Melanoma
Phase 1CompletedImmutep Australia Pty. Ltd.242016-04-012019-12-18
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
Indoximod, Ipilimumab, Nivolumab - Metastatic Melanoma, Stage III Melanoma
Phase 1 / Phase 2CompletedNewLink Genetics Corporation1312014-07-012026-05-29
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma
therapeutic autologous lymphocytes, aldesleukin, denileukin diftitox - Recurrent Melanoma, Stage III Melanoma
Phase 1 / Phase 2TerminatedFred Hutchinson Cancer Center32009-07-012022-11-15
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
sorafenib tosylate, temsirolimus - Melanoma, Recurrent Melanoma
Phase 1CompletedNational Cancer Institute (NCI)692006-04-012014-04-10
Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery
recombinant interferon alfa-2b, amifostine/azacitidine - Recurrent Melanoma, Recurrent Renal Cell Cancer
Phase 1CompletedNational Cancer Institute (NCI)422005-07-012013-05-03
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
alvespimycin hydrochloride, laboratory biomarker analysis, pharmacological study - Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Phase 1CompletedNational Cancer Institute (NCI)302004-07-012013-04-10
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
imatinib mesylate, bevacizumab, pharmacological study - Recurrent Melanoma, Stage III Melanoma
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)402003-10-012018-06-20
Decitabine in Treating Patients With Advanced Solid Tumors
decitabine, pharmacological study, laboratory biomarker analysis - Male Breast Cancer, Recurrent Bladder Cancer
Phase 1CompletedNational Cancer Institute (NCI)242001-12-012013-02-07

Narrower conditions

Melanoma (10)  ·  Breast Neoplasms (2)  ·  Breast Neoplasms, Male (2)  ·  Carcinoma, Renal Cell (2)  ·  Carcinoma, Ovarian Epithelial (1)  ·  Colonic Neoplasms (1)  ·  Esthesioneuroblastoma, Olfactory (1)  ·  Prostatic Neoplasms (1)  ·  Salivary Gland Neoplasms (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)  ·  Stomach Neoplasms (1)  ·  Urinary Bladder Neoplasms (1)

Broader conditions

Neoplasms (10)  ·  Neoplasms by Histologic Type (10)  ·  Neoplasms by Site (10)  ·  Neoplasms, Germ Cell and Embryonal (10)  ·  Neoplasms, Nerve Tissue (10)  ·  Neuroectodermal Tumors (10)  ·  Neuroendocrine Tumors (10)  ·  Nevi and Melanomas (10)  ·  Skin Diseases (10)  ·  Skin Neoplasms (10)  ·  Skin and Connective Tissue Diseases (10)  ·  Female Urogenital Diseases (3)  ·  Female Urogenital Diseases and Pregnancy Complications (3)  ·  Male Urogenital Diseases (3)  ·  Urogenital Diseases (3)

Interventions

pembrolizumab (3)  ·  1-methyltryptophan (1)  ·  17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (1)  ·  Amifostine (1)  ·  Azacitidine (1)  ·  Bevacizumab (1)  ·  Biopsy (1)  ·  Decitabine (1)  ·  Imatinib Mesylate (1)  ·  Immunohistochemistry (1)  ·  Interleukin-2 (1)  ·  Introns (1)  ·  Ipilimumab (1)  ·  Nivolumab (1)  ·  Polymerase Chain Reaction (1)

Sponsors

National Cancer Institute (NCI) (5)  ·  Fred Hutchinson Cancer Center (1)  ·  Immutep Australia Pty. Ltd. (1)  ·  NewLink Genetics Corporation (1)  ·  Taiga Biotechnologies, Inc. (1)  ·  University of Colorado, Denver (1)

Countries

United States (9)  ·  Australia (1)

Top investigators

David Solit (1)  ·  Jeffrey Weber (1)  ·  Keith Flaherty (1)  ·  Kevin Kim (1)  ·  Mario Sznol (1)  ·  Martin McCarter, MD (1)  ·  Sylvia Lee (1)

NIH funding

K12CA076930 (1), N01CM62202 (1), P30CA016672 (1), R21CA137647 (1), U01CA062505 (1), U01CA069856 (1)